A World Without Infectious Disease
Phil Pang, M.D., Ph.D.
Executive Vice President, Chief Medical Officer and Interim Head of Research
Dr. Pang serves as Executive Vice President, Chief Medical Officer and Interim Head of Research for Vir, where he is responsible for overseeing the Company’s global clinical development portfolio. His career in industry has been dedicated to the development of novel therapies to address some of the world’s most challenging infectious diseases. Since joining the company in 2016, Dr. Pang has advanced numerous compounds from early-to late-stage clinical development, including sotrovimab, a monoclonal antibody treatment for COVID-19, which is now authorized for use or approved in more than a dozen countries.
Prior to joining Vir, Dr. Pang served as Chief Medical Officer of Riboscience LLC, a Roche-spinoff developing small molecule antivirals. Previously, during his four-year tenure as Program Lead at Gilead Sciences, Inc., Dr. Pang led a large matrix team to the successful worldwide approval of the first one-pill, once-a-day hepatitis C treatment.
Dr. Pang received his bachelor’s degree in biological sciences from Stanford University and holds a Ph.D. in biochemistry and biophysics from Columbia University. His dissertation focused on viral molecular motors. He obtained his M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed his fellowship in infectious diseases at Stanford University.